Presented in part at the 22nd European Hematology Association Congress, held June 22–25, 2017, in Madrid, Spain; the 5th Society of Hematologic Oncology Annual Meeting, held September 13–16, 2017, in Houston, Texas; and the 59th Annual Meeting and Exposition of the American Society of Hematology, held December 9–12, 2017, in Atlanta, Georgia.
ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.
Attempting TFR required ≥ 3 years of nilotinib, a molecular response of MR4.5 [BCR-ABL1 ≤ 0.0032% on the International Scale (BCR-ABL1IS)], and sustained deep molecular response (DMR) during a 1-year consolidation phase. Patients restarted nilotinib following loss of major molecular response (MMR; BCR-ABL1IS ≤ 0.1%).
Ninety-six weeks after stopping treatment (3.6-year median prior nilotinib duration), 93 of 190 patients (48.9%) remained in TFR. Of 88 patients who restarted nilotinib following loss of MMR, 87 regained MMR and 81 regained MR4.5 by the data cut-off. Ninety-six-week TFR rates were 61.3, 50.0, and 28.6% in patients with low, intermediate, and high Sokal risk scores at diagnosis, respectively. Patients consistently in MR4.5 during consolidation had higher TFR rates (50.6%) than patients with ≥ 1 assessment without MR4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR4.5, MR4 (BCR-ABL1IS ≤ 0.01%) but not MR4.5, and MMR but not MR4 at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.
These results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR.
Boquimpani CM, Szczudlo T, Mendelson E, Benjamin K, Masszi T (2014) Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR). Blood 124(21):[abstract 4547]
Hochhaus A, Saglio G, Hughes TP et al (2015) Impact of treatment with frontline nilotinib (NIL) vs imatinib (IM) on sustained deep molecular response (MR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 126(23):[abstract 2781]
Hughes TP, Boquimpani C, Kim D et al (2016) Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): first results from the ENESTop study. J Clin Oncol 34(suppl):[abstract 7054]
Imagawa J, Tanaka H, Okada M et al (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2(12):e528–e535. https://doi.org/10.1016/S2352-3026(15)00196-9 CrossRef
Lee SE, Choi SY, Song HY et al (2016) Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101(6):717–723. https://doi.org/10.3324/haematol.2015.139899 CrossRefPubMedPubMedCentral
Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029–1035. https://doi.org/10.1016/S1470-2045(10)70233-3 CrossRefPubMed
Nakamae H, Imagawa J, Tanaka H et al (2017) Final study results of discontinuation of dasatinib in patients with CML who maintained deep molecular response for longer than one year (DADI trial) after three years of follow-up. Haematologica 102(s2):77 [abstract P263]
National Comprehensive Cancer Network (2017) NCCN clinical practice guidelines in oncology: chronic myeloid leukemia. V3.2018
Novartis Pharmaceuticals Corporation (2017a) Tasigna (nilotinib) [package insert]. East Hanover, New Jersey
Novartis Pharmaceuticals Corporation (2017b) Tasigna (nilotinib) [summary of product characteristics]. Camberley, UK
Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32(5):424–430. https://doi.org/10.1200/JCO.2012.48.5797 CrossRefPubMed
Saussele S, Richter J, Guilhot J et al (2017) “Duration of deep molecular response” has most impact on the success of cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia—results from the EURO-SKI trial. Blood 130(suppl 1):[abstract 313]
Shah NP, Gutiérrez VG, Jiménez-Velasco A et al (2017) Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE). Blood 130(Suppl 1):[abstract 314]
Villemagne Sanchez LA, O’Callaghan C, Gough K et al (2018) Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma 59(2):406–415. https://doi.org/10.1080/10428194.2017.1337114 CrossRefPubMed
- Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
David M. Ross
María Teresa Gómez Casares
Philipp D. le Coutre
Francis J. Giles
Jerald P. Radich
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II